quercetin hydrogel

Overview

Quercetin hydrogel is a quercetin-containing hydrogel formulation designed to deliver the flavonoid quercetin in a localized, sustained, or otherwise bioavailable form. quercetin itself is a naturally occurring polyphenolic flavonoid widely found in medicinal and edible plants and is studied for a range of biological activities, including anti-inflammatory, antioxidant, barrier-protective, and anticancer effects. In hydrogel form, quercetin is incorporated into a polymeric or self-assembling matrix to improve handling, retention at the target site, and therapeutic performance.

In biomedical research, quercetin hydrogel is of interest as a drug-delivery and tissue-repair platform rather than as a single molecular target. The available recent literature links quercetin-based interventions to cancer-related signaling pathways such as IGF1 and EGFR, as well as to intestinal mucosal protection and wound healing. In the specific hydrogel study context, the formulation was investigated as a self-assembling system derived from Astragalus membranaceus and was reported to accelerate diabetic wound healing, suggesting a role in regenerative medicine and local therapy.

Focus of Latest Publications

I've reviewed the provided abstracts and encountered a significant issue: only one abstract (PMID 41966023) explicitly concerns quercetin hydrogel, and that abstract is incomplete—it contains only background/introduction text, not the actual findings section.

The remaining 11 abstracts study quercetin in other delivery systems:

• Nanoparticles (PMID 42360515)
• Niosomes (PMID 42332019)
• Nanoemulsions (PMID 42304318)
• Solid lipid nanoparticles (PMID 42267862)
• As a component in herbal formulas (PMID 42054904, 42285688)
• As a compound alone (PMID 42295420, 42284354, 42319401, 42030882, 41962406)

To write the "Focus of Latest Publications" section accurately, I need:

1. The complete abstract for PMID 41966023 (results/findings section), since that's the only quercetin hydrogel study
2. Confirmation that the other 11 abstracts are intentionally included as mechanistic context, or replacement with abstracts specifically about quercetin hydrogel formulations/applications

Can you provide the complete abstract text for PMID 41966023, or clarify whether I should write this section based solely on that one study plus extract mechanistic insights from the other quercetin studies (which wouldn't strictly be "focus of quercetin hydrogel" publications)?

Key Publications

• NEWJul A network pharmacology-based approach and molecular docking study to explore the therapeutic potential of a nutraceutical formula (Vernolac) in the treatment of cancer. (PloS one, 2026, PMID 42384725): "Network analyses highlighted key phytochemicals, including vernolactone, thymoquinone, quercetin, nigellidine, α-hederin, and carvacrol."
• NEWJun Preparation and In Vitro Characterization of Quercetin and Chlorhexidine-loaded PLGA Nanoparticles for Oral Biofilm-Associated Pathologies. (Clinical oral investigations, 2026, PMID 42360515): "This study aimed to develop and evaluate a dual-drug-loaded PLGA nanoparticle system incorporating quercetin (QUE) and chlorhexidine (CHX) for localized, sustained delivery, with potential application in biofilm-associated pathologies."
• NEWJun Niosomal l-carnitine and quercetin improve sperm quality and testicular function in atrazine-induced reproductive toxicity in rats. (Scientific reports, 2026, PMID 42332019): "L-carnitine (LC) and quercetin (QT) possess antioxidant properties, rendering them viable additional treatments for male infertility."
• NEWJun Decoding chromatin regulator-LAIR1+ M2 like macrophage patterns in atherosclerosis and clinical outcomes of Lung adenocarcinoma patients: evidence from artificial intelligence-driven multi omics and in vitro validation. (Clinical and experimental medicine, 2026, PMID 42319401): "Quercetin was identified as potential preventive agent for AS in LUAD patients."
• NEWJun Low-energy spontaneous fabrication of quercetin-loaded orange oil nanoemulsion for induction of colorectal cancer cell apoptosis. (BMC complementary medicine and therapies, 2026, PMID 42304318): "quercetin, cold-pressed orange peel oil, and their mixture in their natural state and in micellar dispersion and nanoemulsions were examined for their activity to induce HCT116 and Caco-2 colorectal cancer cells to apoptosis."
• NEWJun Quercetin targets IGF1 signaling in gastric cancer: a synergy of network pharmacology, molecular simulations, and in vitro functional assays. (Journal of computer-aided molecular design, 2026, PMID 42295420): "Quercetin, a natural flavonoid, has demonstrated anticancer activity; however, its molecular mechanism, particularly its effect on key targets in GC, remains underexplored."
• NEWJun Quercetin suppresses the progression of HBV-associated hepatocellular carcinoma by modulating the EGFR signaling pathway. (PloS one, 2026, PMID 42284354): "Quercetin, a bioactive flavonoid compound widely present in medicinal and edible plants, has demonstrated therapeutic potential against hepatocellular carcinoma (HCC)."
• NEWJul Dual targeting of cutaneous inflammation and vasculopathy via STING-NF-κB blockade underlies the anti-psoriatic efficacy of Yinxie Granules. (Chinese journal of natural medicines, 2026, PMID 42285688): "Quercetin and kaempferol were identified as the primary STING-modulating components in YXKL, binding to STING proteins and inhibiting downstream pathway activation."
• NEWJun Integrin αvβ3-Targeted SLNs for Co-Delivery of Paclitaxel and Quercetin in Triple-Negative Breast Cancer. (ACS applied materials & interfaces, 2026, PMID 42267862): "Although paclitaxel and quercetin (PTX/Q) have been explored as complementary agents, their concurrent use is limited by poor solubility, rapid systemic clearance, and dose-related toxicities."
• Jun UPLC-Q-TOF-MS/MS-based dynamic metabolite profile analysis of Huangkui capsule in serum, urine, and feces from normal and pseudo-germ-free rats. (Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2026, PMID 42054904): "HKC metabolism involved phase I biotransformations (mainly in quercetin-HRX) and phase II conjugations (mainly in gossypetin-HRX)."